Literature DB >> 31880529

Mesenchymal stem cell-derived exosomes improve diabetes mellitus-induced myocardial injury and fibrosis via inhibition of TGF-β1/Smad2 signaling pathway.

Yuan Lin1, Fang Zhang1, Xiao-Fen Lian1, Wei-Qun Peng1, Chao-Yao Yin1.   

Abstract

The aim of this study is to investigate  the effect of mesenchymal stem cell (MSC)-derived exosomes on diabetes mellitus-induced myocardial injury, and the underlying mechanism. Thirty adult male Sprague Dawley rats were randomly assigned to three groups of ten rats each: normal control group, diabetic control group and MSC exosomes group. Exosomes were isolated from MSCs through gradient ultracentrifugation. With the exception of normal control, diabetes mellitus (DM) was induced in the rats with a single intraperitoneal injection of 30 mg/kg body weight streptozotocin (STZ) in 0.1 mol/L sodium citrate buffer. Rats in MSC exosomes group were intravenously injected with MSC-derived exosomes once a week for 12 weeks. Left ventricular collagen (LVC) level was measured using acid hydrolysis method. Fatty acid transporters (FATPs) and fatty acid beta oxidase (FA-β-oxidase) were determined using enzyme-linked immunosorbent assay (ELISA). Gene and protein expressions of TGF-β and Smad2 were determined using real-time quantitative polymerase chain reaction (qRT-PCR) and Western blotting. Flow cytometric analysis and Western blotting revealed positive expression of exosomal specific marker, CD63. The level of LVC was significantly higher in diabetic control group than in normal control group, but was significantly reduced after treatment with MSC-derived exosomes (p < 0.05). The levels of FATPs and FA-β-oxidase were significantly lower in diabetic control group than in normal control group (p < 0.05). However, treatment with MSC-derived exosomes significantly increased the levels of these proteins (p < 0.05). The levels of expression of TGF-β1 and Smad2 mRNAs were significantly higher in the diabetic control group than in normal control group, but were significantly reduced after treatment with MSC-derived exosomes (p < 0.05). The expressions of TGF-β1 and Smad2 proteins were also significantly upregulated in diabetic control group, when compared with normal control group (p < 0.05). However, treatment with MSC-derived exosomes significantly down-regulated the expression of these proteins (p < 0.05). The results obtained in this study indicate that MSC-derived exosomes improve DM-induced myocardial injury and fibrosis via inhibition of TGF-β1/Smad2 signaling pathway.

Entities:  

Keywords:  Diabetes mellitus; Diabetic cardiomyopathy; Expression.; Fibrosis; Mesenchymal stem cell-derived exosomes

Mesh:

Substances:

Year:  2019        PMID: 31880529

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  14 in total

Review 1.  Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review.

Authors:  Vilim Molnar; Eduard Pavelić; Kristijan Vrdoljak; Martin Čemerin; Emil Klarić; Vid Matišić; Roko Bjelica; Petar Brlek; Ivana Kovačić; Carlo Tremolada; Dragan Primorac
Journal:  Genes (Basel)       Date:  2022-05-26       Impact factor: 4.141

2.  Therapeutic effects of in vivo-differentiated stem cell and Matricaria chamomilla L. Oil in diabetic rabbit.

Authors:  Afsaneh Fazili; Soghra Gholami; Mojgan Sheikhpour; Pegah Pousti
Journal:  J Diabetes Metab Disord       Date:  2020-05-11

Review 3.  Therapeutic Potentials of Extracellular Vesicles for the Treatment of Diabetes and Diabetic Complications.

Authors:  Wei Hu; Xiang Song; Haibo Yu; Jingyu Sun; Yong Zhao
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

Review 4.  Clinical Potential of Extracellular Vesicles in Type 2 Diabetes.

Authors:  Jie Liu; Xin Sun; Fu-Liang Zhang; Hang Jin; Xiu-Li Yan; Shuo Huang; Zhen-Ni Guo; Yi Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-21       Impact factor: 5.555

Review 5.  Mesenchymal Stem Cell Exosomes as a New Strategy for the Treatment of Diabetes Complications.

Authors:  Jiachao Xiong; Hao Hu; Rong Guo; Hui Wang; Hua Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-29       Impact factor: 5.555

6.  Exosomal hsa_circ_0125310 promotes cell proliferation and fibrosis in diabetic nephropathy via sponging miR-422a and targeting the IGF1R/p38 axis.

Authors:  Yingchun Zhu; Fangfang Zha; Bo Tang; Ting-Ting Ji; Xiao-Ying Li; Linhong Feng; Shou-Jun Bai
Journal:  J Cell Mol Med       Date:  2021-12-02       Impact factor: 5.310

Review 7.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

8.  Exosomes derived from mesenchymal stem cells inhibit neointimal hyperplasia by activating the Erk1/2 signalling pathway in rats.

Authors:  Zhihui Liu; Chao Wu; Xinliang Zou; Weiming Shen; Jiacai Yang; Xiaorong Zhang; Xiaohong Hu; Haidong Wang; Yi Liao; Tao Jing
Journal:  Stem Cell Res Ther       Date:  2020-06-08       Impact factor: 6.832

Review 9.  Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy.

Authors:  Jaqueline S da Silva; Renata G J Gonçalves; Juliana F Vasques; Bruna S Rocha; Bianca Nascimento-Carlos; Tadeu L Montagnoli; Rosália Mendez-Otero; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

10.  Adipose-Derived Mesenchymal Stem Cells-Derived Exosomes Carry MicroRNA-671 to Alleviate Myocardial Infarction Through Inactivating the TGFBR2/Smad2 Axis.

Authors:  Xue Wang; Yuhai Zhu; Chengcheng Wu; Wennan Liu; Yujie He; Qing Yang
Journal:  Inflammation       Date:  2021-04-21       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.